Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection-Reference-Cited by-同舟云学术

Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection

Published:2020-01-22 Issue:2 Volume:80 Page:189-196
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Blair Hannah A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-020-01258-3.pdf

Reference37 articles.

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019. https://aidsinfo.nih.gov/guidelines. Accessed 6 Jan 2020.

2. European AIDS Clinical Society. Guidelines version 9.1. 2018. https://eacsociety.org. Accessed 6 Jan 2020.

3. Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. Front Microbiol. 2017;8:2323.

4. Grover D, Copas A, Green H, et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 2008;61(3):705–13.

5. Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS. 2005;19(10):1081–9.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Ibalizumab for the treatment of HIV-1 infected patients: A systematic review;Global Journal of Health Sciences and Research;2024-08-26

2. Nucleoside Reverse Transcriptase Inhibitors Are the Major Class of HIV Antiretroviral Therapeutics That Induce Neuropathic Pain in Mice;International Journal of Molecular Sciences;2024-08-21

3. Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration;Nature Communications;2024-08-13

4. Oral intolerance: new scenario for parenteral antiretroviral therapy;Enfermedades infecciosas y microbiologia clinica (English ed.);2024-08

5. Advanced Therapies for Human Immunodeficiency Virus;Medical Sciences;2024-07-18